{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:55:31Z","timestamp":1792788931164,"version":"4.5.0"},"reference-count":67,"publisher":"Informa UK Limited","issue":"14","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Bayer Healthcare Pharmaceuticals, Inc."}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.2217\/fon-2023-0814","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T04:41:07Z","timestamp":1707885667000},"page":"903-918","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":31,"title":["Real-world treatment of metastatic hormone-sensitive prostate cancer in the USA, Europe and Asia"],"prefix":"10.1080","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0176-4478","authenticated-orcid":false,"given":"Peter J","family":"Goebell","sequence":"first","affiliation":[{"name":"Division of Urology, University Hospital Erlangen, 91054, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1585-4514","authenticated-orcid":false,"given":"Rutika","family":"Raina","sequence":"additional","affiliation":[{"name":"OPEN Health, Bethesda, MD20814, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4103-5672","authenticated-orcid":false,"given":"Stephanie","family":"Chen","sequence":"additional","affiliation":[{"name":"Bayer Healthcare Pharmaceuticals, Inc., Whippany, NJ07981, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2405-0147","authenticated-orcid":false,"given":"Sanika","family":"Rege","sequence":"additional","affiliation":[{"name":"OPEN Health, Bethesda, MD20814, USA"},{"name":"Present address: Center for Pharmacoepidemiology & Treatment Science, Rutgers University, New Brunswick, NJ08901, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3553-6142","authenticated-orcid":false,"given":"Ruchit","family":"Shah","sequence":"additional","affiliation":[{"name":"OPEN Health, Bethesda, MD20814, USA"},{"name":"Present address: Daiichi Sankyo, Inc., Basking Ridge, NJ07920, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9358-8971","authenticated-orcid":false,"given":"Jamie Partridge","family":"Grossman","sequence":"additional","affiliation":[{"name":"Bayer Healthcare Pharmaceuticals, Inc., Whippany, NJ07981, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2351-9338","authenticated-orcid":false,"given":"A Reginald","family":"Waldeck","sequence":"additional","affiliation":[{"name":"Bayer Healthcare Pharmaceuticals, Inc., Whippany, NJ07981, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_8_4_1","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1191"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11091355"},{"key":"e_1_3_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30082-8"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.11.005"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70560-0"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1702900"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01037-5"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.3657"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1701695"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747"},{"key":"e_1_3_8_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119115"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00367-1"},{"key":"e_1_3_8_16_1","unstructured":"Ipsos . Therapy insights centres of expertise. www.ipsos.com\/en\/healthcare-therapy-insights-centres-expertise (Accessed January 2024)."},{"key":"e_1_3_8_17_1","unstructured":"Ipsos . Ipsos real world evidence: a compendium of usage 2018\u20132021. www.ipsos.com\/sites\/default\/files\/2022-01\/Ipsos-Syndicated-Real-World-Evidence-Compendium_October-2021.pdf (Accessed January 2024)."},{"key":"e_1_3_8_18_1","unstructured":"NICE: National Institute for Health and Care Excellence . Single technology appraisal: pembrolizumab for previously treated advanced or metastatic urothelial cancer (CDF review TA519) [ID1536] - Committee papers. www.nice.org.uk\/guidance\/ta692\/documents\/committee-papers-2 (2020)."},{"key":"e_1_3_8_19_1","unstructured":"Gemeinsamer Bundesausschuss . Dossier zur Nutzenbewertung gem\u00e4\u00df \u00a7 35a SGB V: radium-223-dichlorid (Xofigo\u00ae); Bayer Vital GmbH Modul 3A. www.g-ba.de\/downloads\/92-975-3055\/2019-04-02_Modul3A_Radium-223-dichlorid.pdf (2019)."},{"key":"e_1_3_8_20_1","unstructured":"CARE Hematology . CARE perspectives: ASCO\/EHA 2018. https:\/\/careeducation.ca\/wp-content\/uploads\/2019\/03\/ASCOEHAReportWeb2.pdf (2018)."},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S343321"},{"key":"e_1_3_8_22_1","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2019-0563"},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.09.2746"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.85"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-21-1845"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00198-X"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.01.228"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad045"},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-022-00979-9"},{"key":"e_1_3_8_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.5074"},{"key":"e_1_3_8_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.5072"},{"key":"e_1_3_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1122"},{"key":"e_1_3_8_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.08.1129"},{"key":"e_1_3_8_34_1","unstructured":"U.S. Food and Drug Administration. Drug approval package: taxotere (docetaxel) injection. www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2004\/20-449s028_Taxotere.cfm (2004)."},{"key":"e_1_3_8_35_1","unstructured":"JNCCN360 Prostate Cancer . Docetaxel (castration-naive metastatic prostate cancer). https:\/\/jnccn360.org\/prostate\/jnccn-spotlights\/docetaxel\/ (2020)."},{"key":"e_1_3_8_36_1","unstructured":"European Medicines Agency . Summary of opinion (post authorisation): taxotere docetaxel. www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-taxotere-ws-1550_en.pdf (2019)."},{"key":"e_1_3_8_37_1","unstructured":"ESMO . EMA recommends extension of indications for Taxotere and Docetaxel Zentiva. www.esmo.org\/oncology-news\/ema-recommends-extension-of-indications-for-taxotere-and-docetaxel-zentiva (2019)."},{"key":"e_1_3_8_38_1","unstructured":"Gemeinsamer Bundesausschuss . Arzneimittel-Richtlinie\/Anlage VI: docetaxel bei hormonsensitivem Prostatakarzinom mit Fernmetastasen (M1) [Drug Directive\/Annex VI: Docetaxel in hormone-sensitive prostate cancer with distant metastases (M1)]. www.g-ba.de\/beschluesse\/3263\/ (2018)."},{"key":"e_1_3_8_39_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 . Taxotere - prostate cancer. www.has-sante.fr\/jcms\/p_3191910\/en\/taxotere-prostate-cancer (2020)."},{"key":"e_1_3_8_40_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S236879"},{"key":"e_1_3_8_41_1","unstructured":"S&P Global Market Intelligence . China releases new basic health insurance formulary all 307 essential drugs listed. www.spglobal.com\/marketintelligence\/en\/mi\/country-industry-forecasting.html?id=106594822 (2009)."},{"key":"e_1_3_8_42_1","unstructured":"Sanofi. Notice of revised usage precautions September 2021. www.e-mr.sanofi.co.jp\/-\/media\/EMS\/Conditions\/eMR\/di\/kaitei\/OTX_TXT_info2021_03.pdf (2021)."},{"key":"e_1_3_8_43_1","unstructured":"U.S. Food and Drug Administration . FDA approves abiraterone acetate in combination with prednisone for high-risk metastatic castration-sensitive prostate cancer. www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-abiraterone-acetate-combination-prednisone-high-risk-metastatic-castration-sensitive (2018)."},{"key":"e_1_3_8_44_1","unstructured":"European Medicines Agency . Summary of opinion (post authorisation): zytiga \/ abiraterone acetate. www.ema.europa.eu\/en\/documents\/smop\/chmp-post-authorisation-summary-positive-opinion-zytiga_en-0.pdf (2017)."},{"key":"e_1_3_8_45_1","unstructured":"Gemeinsamer Bundesausschuss . Arzneimittel-Richtlinie\/Anlage XII: Abirateronacetat (neues Anwendungsgebiet: metastasiertes hormonsensitives Prostatakarzinom [mHSPC]) [Drug Directive\/Annex XII: Abiraterone acetate (new field of application: metastatic hormone-sensitive prostate cancer [mHSPC])]. www.g-ba.de\/beschluesse\/3360\/ (2018)."},{"key":"e_1_3_8_46_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 . ZYTIGA (abiraterone acetate) androgen synthesis inhibitor. www.has-sante.fr\/jcms\/c_2857377\/en\/zytiga-abiraterone-acetate-androgen-synthesis-inhibitor (2018)."},{"key":"e_1_3_8_47_1","unstructured":"Xi\u2019an Janssen Pharmaceutical Co. Ltd . Xi\u2019an Janssen\u2019s Zeke\u00ae approved for new indication in China for the treatment of high-risk metastatic endocrine therapy-sensitive prostate cancer. www.xian-janssen.com.cn\/news\/717 (2018)."},{"key":"e_1_3_8_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2021-006196"},{"key":"e_1_3_8_49_1","unstructured":"New drugs approved in FY 2017. www.pmda.go.jp\/files\/000232769.pdf"},{"key":"e_1_3_8_50_1","unstructured":"U.S. Food and Drug Administration . FDA approves enzalutamide for metastatic castration-sensitive prostate cancer. www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-enzalutamide-metastatic-castration-sensitive-prostate-cancer (2019)."},{"key":"e_1_3_8_51_1","unstructured":"ESMO . EMA recommends extension of indications for enzalutamide. www.esmo.org\/oncology-news\/ema-recommends-extension-of-indications-for-enzalutamide (2021)."},{"key":"e_1_3_8_52_1","unstructured":"Gemeinsamer Bundesausschuss . Nutzenbewertungsverfahren zum Wirkstoff Enzalutamid (Neues Anwendungsgebiet: prostatakarzinom metastasiert hormonsensitiv Kombination mit Androgenentzugstherapie) [Benefit assessment procedure for the active ingredient enzalutamide (new indication: prostate carcinoma metastatic hormone-sensitive combination with androgen deprivation therapy)]. www.g-ba.de\/bewertungsverfahren\/nutzenbewertung\/696\/#english (2021)."},{"key":"e_1_3_8_53_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 . XTANDI (enzalutamide) -Extension d\u2019indication [XTANDI (enzalutamide) -Extension of indication]. www.has-sante.fr\/jcms\/p_3284790\/fr\/xtandi-enzalutamide (2021)."},{"key":"e_1_3_8_54_1","unstructured":"Astellas . XTANDI\u00ae (enzalutamide) approved by Japan MHLW for the treatment of prostate cancer with distant metastasis. www.astellas.com\/en\/news\/15876 (2020)."},{"key":"e_1_3_8_55_1","unstructured":"FDA approves apalutamide for metastatic castration-sensitive prostate cancer. www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-apalutamide-metastatic-castration-sensitive-prostate-cancer (2019)."},{"key":"e_1_3_8_56_1","unstructured":"European Medicines Agency . Erleada - apalutamide. www.ema.europa.eu\/en\/medicines\/human\/EPAR\/erleada (2021)."},{"key":"e_1_3_8_57_1","unstructured":"IQWiG - Institute for Quality and Efficiency in Healthcare . Apalutamide (prostate cancer) \u2013 Benefit assessment according to \u00a735a Social Code Book - IQWiG Reports - Commission No. A20-20. www.iqwig.de\/download\/a20-20_apalutamide_extract-of-dossier-assessment_v1-0.pdf (2020)."},{"key":"e_1_3_8_58_1","unstructured":"Haute Autorit\u00e9 de Sant\u00e9 . Apalutamide - ERLEADA 60 mg comprim\u00e9 pellicul\u00e9 - nouvelle indication [Apalutamide - ERLEADA 60 mg coated tablet - new indication]. www.has-sante.fr\/upload\/docs\/evamed\/CT-18482_ERLEADA_PIC_EI_AvisDef_CT18482.pdf (2020)."},{"key":"e_1_3_8_59_1","unstructured":"Home Sunshine Pharma . Erleada was approved in China for a new indication for the treatment of metastatic endocrine therapy-sensitive prostate cancer. www.hsppharma.com\/news\/erleada-was-approved-in-china-for-a-new-indica-37418604.html (2020)."},{"key":"e_1_3_8_60_1","unstructured":"News alert: China\u2019s 2021 NRDL welcomes 67 new additions at an average 62% price reduction. www.eversana.com\/2021\/12\/06\/news-alert-chinas-2021-nrdl-welcomes-67-new-additions-at-an-average-62-price-reduction\/ (2021)."},{"key":"e_1_3_8_61_1","unstructured":"Nippon Shinyaku Co. Ltd . MHLW approval of ERLEADA\u00ae (apalutamide) for the treatment of patients with prostate cancer with distant metastases. www.nippon-shinyaku.co.jp\/file\/download.php?file_id=3873 (2020)."},{"key":"e_1_3_8_62_1","unstructured":"National Comprehensive Cancer Network . Prostate cancer v 4.2018 - August 15 2018. www2.tri-kobe.org\/nccn\/guideline\/archive\/urological2018\/english\/prostate.pdf (2018)."},{"key":"e_1_3_8_63_1","unstructured":"National Comprehensive Cancer Network . Prostate cancer v. 4.2019 - 19 August 2019. www2.tri-kobe.org\/nccn\/guideline\/urological\/english\/prostate.pdf (2019)."},{"key":"e_1_3_8_64_1","unstructured":"NCCN Guidelines for Patients . Prostate cancer - Advanced stage. www.nccn.org\/patients\/guidelines\/content\/PDF\/prostate-advanced-patient.pdf (2022)."},{"key":"e_1_3_8_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2017.09.029"},{"key":"e_1_3_8_66_1","unstructured":"EAU Guidelines: prostate cancer 2019. https:\/\/uroweb.org\/guidelines\/prostate-cancer\/summary-of-changes\/2019 (2019)."},{"key":"e_1_3_8_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.046"},{"key":"e_1_3_8_68_1","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2019.01.04"},{"key":"e_1_3_8_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13380"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2023-0814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,19]],"date-time":"2024-09-19T10:30:25Z","timestamp":1726741825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2023-0814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":67,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.2217\/fon-2023-0814"],"URL":"https:\/\/doi.org\/10.2217\/fon-2023-0814","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-09-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-01-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-02-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}